Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kezar Life Sciences (KZR) Retained Earnings (2021 - 2025)

Kezar Life Sciences' Retained Earnings history spans 5 years, with the latest figure at -$476.0 million for Q3 2025.

  • For Q3 2025, Retained Earnings fell 14.89% year-over-year to -$476.0 million; the TTM value through Sep 2025 reached -$476.0 million, down 14.89%, while the annual FY2024 figure was -$162000.0, 99.95% up from the prior year.
  • Retained Earnings for Q3 2025 was -$476.0 million at Kezar Life Sciences, down from -$464.8 million in the prior quarter.
  • Across five years, Retained Earnings topped out at -$140000.0 in Q1 2021 and bottomed at -$476.0 million in Q3 2025.
  • The 5-year median for Retained Earnings is -$152.0 million (2021), against an average of -$173.2 million.
  • The largest annual shift saw Retained Earnings surged 99.95% in 2024 before it tumbled 120627.27% in 2025.
  • A 5-year view of Retained Earnings shows it stood at -$291000.0 in 2021, then tumbled by 217.18% to -$923000.0 in 2022, then plummeted by 37902.49% to -$350.8 million in 2023, then soared by 99.95% to -$162000.0 in 2024, then tumbled by 293718.52% to -$476.0 million in 2025.
  • Per Business Quant, the three most recent readings for KZR's Retained Earnings are -$476.0 million (Q3 2025), -$464.8 million (Q2 2025), and -$232000.0 (Q1 2025).